Close to 20 million Americans, or 10% of US population, suffer from the chronic kidney disease (CKD). Among a plethora of cardiovascular manifestations, CKD patients are particularly at a high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula creation). This area of CKD management warrants urgent investigation due to the lack of risk predictors and CKD-specific therapeutic targets.<\/p>\n
Renal failure results in the retention of several chemical compounds, which unleash cellular toxicity and hence called uremic solutes\/toxins. While investigating the molecular pathogenesis of uremic toxicity, our laboratory was the first to demonstrate the prothrombotic propensity of indolic uremic solutes which inhibit the ubiquitination of tissue factor, a bona fide member of the extrinsic coagulation pathway. Further investigation revealed Aryl Hydrocarbon Receptor (AHR) pathway as a critical mediator of tissue factor ubiquitination and thrombosis. Leveraging the ligand and the mediator, our lab aims to gain a deeper understanding of the mechanism of this unique uremic thrombosis axis (uremic solutes- AHR- TF- thrombosis). In addition, we yearn to develop biomarkers and novel compounds to improve the management of the CKD patients with thrombosis after interventions in various vascular beds including coronary artery and arteriovenous fistula, etc.<\/p>\n
Thrombosis, being a dynamic and multicomponent process, our laboratory has taken a holistic approach, under the co-directorship of Drs. Chitalia and Ravid, the Department of Medicine of BUSM, and established a Thrombosis and Hemostasis ARC which is a multidisciplinary platform of cell and molecular biologists, clinicians (cardiologists, vascular medicine, nephrologists and hematologists), computational biologists, biomedical engineers and statisticians and mathematicians to investigate various facets of thrombosis. http:\/\/www.bumc.bu.edu\/evanscenteribr\/the-arcs\/the-arcs\/<\/a><\/p>\n Close to 20 million Americans, or 10% of US population, suffer from the chronic kidney disease (CKD). Among a plethora of cardiovascular manifestations, CKD patients are particularly at a high risk for both venous and arterial thrombosis, especially after vascular injury (endovascular injury such as angioplasty or stents; and surgical injury such as arteriovenous fistula […]<\/p>\n","protected":false},"author":12359,"featured_media":0,"parent":461,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-templates\/no-sidebars.php","meta":[],"_links":{"self":[{"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/pages\/28"}],"collection":[{"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/users\/12359"}],"replies":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/comments?post=28"}],"version-history":[{"count":16,"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/pages\/28\/revisions"}],"predecessor-version":[{"id":1432,"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/pages\/28\/revisions\/1432"}],"up":[{"embeddable":true,"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/pages\/461"}],"wp:attachment":[{"href":"https:\/\/sites.bu.edu\/chitalialab\/wp-json\/wp\/v2\/media?parent=28"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}